Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Eltrombopag 25 mg vs Revolade 25 mg in healthy Thai volunteers (fasting, replicated crossover)
TCTR20260326007Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of eltrombopag (2 arms), sponsored by Bio-innova. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
eltrombopag
Beyond the preview
Go deeper on TCTR20260326007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260326007.